0
Abstract: Slide Presentations |

Comparison of Lower Doses of Recombinant Human Erythropoietin (rHuEPO) in Reducing Transfusions in the Critically Ill FREE TO VIEW

Leo C. Rotello, MD; Dan Albrant, Pharm D; Tet W. Chan, MD; Joseph Fontana, MD; Melissa Means-Markwell, MD; Thaddeus Golden, MD; Andrea Gumlia, RN; Thomas Rainey, MD
Author and Funding Information

Suburban Hospital, Rockville, MD


Chest


Chest. 2003;124(4_MeetingAbstracts):126S-a-127S. doi:10.1378/chest.124.4_MeetingAbstracts.126S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  Critically ill patients have been estimated to have transfusion requirements of between 1 and 2 units per week in the ICU. We previously demonstrated that the administration of rHuEPO at a dose of 450u/kg/wk SQ of was effective in decreasing the need for transfusions in critically ill patients. We prospectively evaluated the ability of a weight based weekly protocol of lower dose (300u/kg/wk) rHuEPO to similarly reduce the need for transfusions.

METHODS:  Patients were eligible for the protocol if they had an anticipated ICU length of stay of one week or greater and a Hct of < 28%. Protocol patients received 300u/kg/wk of rHuEPO. Transfusions were recorded beginning 7 days after entry. No transfusion protocol was implemented. All patients had transferrin levels measured upon entry and at two-week intervals with iron supplementation as indicated.

RESULTS:  450 u/kg/wk rHuEPO*300u/kg/wk rHuEPOn5461Average age74.766.4Average # doses rHuEPO3.1(r1–10)3.0(r1–7)Average dose of rHuEPO28000 units22000 unitsPredicted transfusions167183Actual transfusions4571Units saved (% reduction)122(73%)112 (61%)*

Previously reported data

CONCLUSION:  Weekly rHuEPO at doses of 300u/kg/wk has a comparable efficacy to 450u/kg/wk in reducing transfusions in critically ill patients.

CLINICAL IMPLICATIONS:  Significant cost and medication savings can be realized by the utilization of rHuEPO at lower than previously described doses while still maintaining efficacy for reduction of transfusions.

DISCLOSURE:  L.C. Rotello, Ortho Biotech.Speakers Bureau

Wednesday, October 29, 2003

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543